In a 4-week naturalistic cohort study using continuous glucose monitoring and ecological momentary assessment, investigators examined whether day-to-day glucose fluctuations are associated with mood...
An extensive Danish population-based study compared sodium-glucose cotransporter-2 inhibitors with glucagon-like peptide-1 receptor agonists to clarify their relative impact on diabetic foot disease, an...
A large observational cohort study published in Annals of Internal Medicine examined the effectiveness of statin therapy for primary prevention in adults with type 2 diabetes stratified by predicted 10-year...
A multicenter trial conducted in China found that an artificial intelligence–based insulin clinical decision support system provided glycemic outcomes comparable to standard therapy administered by senior...
The Trump administration announced a new agreement with pharmaceutical companies Eli Lilly and Company and Novo Nordisk to reduce the cost of obesity medication and expand access to these treatments.
As the clinical use of GLP-1 receptor agonists (RA) expands beyond diabetes and obesity, clinicians must balance emerging cardiometabolic and organ-specific benefits with the challenges of persistent...
In adults with type 1 diabetes and obesity using automated insulin delivery, once-weekly semaglutide significantly improved time in range, lowered HbA1c, and reduced body weight by nearly 9 kg compared with...
Large-scale evidence shows perioperative dexamethasone reduces infection risk and shortens hospital stay in patients with diabetes undergoing joint arthroplasty, though hyperglycemia remains a concern.
...
In a nationally representative cohort, adolescents and young adults with optimal cardiovascular health later had lower risks of gestational diabetes and hypertensive disorders of pregnancy than peers with...
A recent study found that daily supplementation with myo-inositol during pregnancy did not reduce the risk of gestational diabetes, preeclampsia, or preterm birth in individuals with polycystic ovary...
